217 related articles for article (PubMed ID: 38296628)
1. [Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].
Deng L; Yang Y; Huang J
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):73-80. PubMed ID: 38296628
[TBL] [Abstract][Full Text] [Related]
2. Targeting
Baik CS; Myall NJ; Wakelee HA
Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
[TBL] [Abstract][Full Text] [Related]
3. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
Turshudzhyan A; Vredenburgh J
Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
[TBL] [Abstract][Full Text] [Related]
4. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
5. BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
Jiang L; Yang P; Liu Y; Li J
J Cancer Res Clin Oncol; 2024 Mar; 150(3):162. PubMed ID: 38538919
[TBL] [Abstract][Full Text] [Related]
6. Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V
Metzenmacher M; Goetz M; Herold T; Stuschke M; Aigner C; Darwiche K; Eberhardt WE; Schuler M; Wiesweg M
Clin Lung Cancer; 2021 Sep; 22(5):e668-e672. PubMed ID: 33551244
[No Abstract] [Full Text] [Related]
7. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
8. Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
Riudavets M; Cascetta P; Planchard D
Lung Cancer; 2022 Jul; 169():102-114. PubMed ID: 35696864
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
10. BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.
Tsamis I; Gomatou G; Chachali SP; Trontzas IP; Patriarcheas V; Panagiotou E; Kotteas E
Clin Transl Oncol; 2023 Jan; 25(1):10-20. PubMed ID: 35729451
[TBL] [Abstract][Full Text] [Related]
11. [Research Progress of BRAF Fusion in Non-small Cell Lung Cancer].
Xiao P; Zhong D
Zhongguo Fei Ai Za Zhi; 2023 Oct; 26(10):782-788. PubMed ID: 37989341
[TBL] [Abstract][Full Text] [Related]
12. [Research Progress of Targeted Therapy for BRAF Mutation
in Advanced Non-small Cell Lung Cancer].
Liu X; Zhong D
Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
14. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
Nguyen-Ngoc T; Bouchaab H; Adjei AA; Peters S
J Thorac Oncol; 2015 Oct; 10(10):1396-403. PubMed ID: 26301799
[TBL] [Abstract][Full Text] [Related]
15. Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.
Sharp JA; Jones D; Rotow JK; Fidias PM; Bertino E; Owen DH
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38479107
[TBL] [Abstract][Full Text] [Related]
16. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Joshi M; Rice SJ; Liu X; Miller B; Belani CP
PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Caparica R; de Castro G; Gil-Bazo I; Caglevic C; Calogero R; Giallombardo M; Santos ES; Raez LE; Rolfo C
Crit Rev Oncol Hematol; 2016 May; 101():32-9. PubMed ID: 26960735
[TBL] [Abstract][Full Text] [Related]
18. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.
Adashek JJ; Menta AK; Reddy NK; Desai AP; Roszik J; Subbiah V
Mol Cancer Ther; 2022 Jun; 21(6):871-878. PubMed ID: 35413124
[TBL] [Abstract][Full Text] [Related]
19. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
Sen B; Peng S; Tang X; Erickson HS; Galindo H; Mazumdar T; Stewart DJ; Wistuba I; Johnson FM
Sci Transl Med; 2012 May; 4(136):136ra70. PubMed ID: 22649091
[TBL] [Abstract][Full Text] [Related]
20. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.
Adamopoulos C; Papavassiliou KA; Poulikakos PI; Papavassiliou AG
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
